Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

NCT01567046 | Completed

• 2 other identifiers: ARST12B5NCI-2012-00714
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

Conditions

Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Chordoma; Desmoid Tumor; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma

Outcome Measures

Primary Outcomes (2)

• Frequency of individual mutated genes in patients with NRSTS

  Up to 1 month

• Genetic changes that are most common and likely to have the greatest therapeutic impact

  Up to 1 month

Study Arms (1)

Correlative studies

Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.

Other: laboratory biomarker analysis

Interventions

laboratory biomarker analysis OTHER

Correlative studies

Correlative studies

Eligibility Criteria

• Age: Up to 30 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Non-rhabdomyosarcoma soft tissue sarcoma

You may qualify if:

• Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA
• Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS
• Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:
• COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol
• COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study
• See Disease Characteristics

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Children's Oncology Group

Monrovia, California, 91006-3776, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Tissue

MeSH Terms

Conditions

Hemangiosarcoma; Desmoplastic Small Round Cell Tumor; Sarcoma; Fibrosarcoma; Liposarcoma; Malignant mesenchymal tumor; Chordoma; Desmoid Tumors

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Vascular Tissue; Neoplasms, Fibrous Tissue; Neoplasms, Connective Tissue; Neoplasms, Adipose Tissue; Neoplasms, Germ Cell and Embryonal; Fibroma

Study Officials

• Steve Skapek, MD

  Children's Oncology Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2012
• First Posted: March 30, 2012
• Study Start: May 1, 2016
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2016
• Last Updated: May 17, 2016

Record last verified: 2016-05

Locations

US (1)